Travere Therapeutics Inc.

Travere Therapeutics Inc. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.

• Travere Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -36.9 M, a 13.50% decrease year-over-year.
• Travere Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -67.3 M, a 81.08% decrease year-over-year.
• Travere Therapeutics Inc. annual operating income for 2025 was -62.8 M, a 80.60% decrease from 2024.
• Travere Therapeutics Inc. annual operating income for 2024 was -323.8 M, a 16.57% decrease from 2023.
• Travere Therapeutics Inc. annual operating income for 2023 was -388.1 M, a 21.36% increase from 2022.
• Travere Therapeutics Inc. annual operating income for 2022 was -319.8 M.